RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Background: Severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2) infections and the resulting disease, coronavirus disease 2019 (COVID−19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. Methods: Healthy a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:medRxiv
Autores principales: Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Mulligan, Mark J, Bailey, Ruth, Swanson, Kena A, Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Thompkins, Kristin R, Lyke, Kirsten E., Raabe, Vanessa, Dormitzer, Philip R, Jansen, Kathrin U, Sahin, Uğur, Gruber, William C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444302/
https://ncbi.nlm.nih.gov/pubmed/32839784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.08.17.20176651
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares